IP Library Granted Patent US 8,932,646
Granted Patent B2
US 8,932,646 · App. 13/012,018 · Granted Jan 13, 2015

Peroxide contact lens care solution

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,932,646
App. No.
13/012,018
Filed
Jan 24, 2011
Granted
Jan 13, 2015
Kind
B2
Art Unit
1616
USPC
424/616
Abstract

A contact lens disinfecting solution that comprises 0.5 wt. % to 6 wt. % hydrogen peroxide, or a chemical precursor of hydrogen peroxide, and a P-metal modulating compound. The presence of the P-metal modulating compound in the disinfecting hydrogen peroxide solution slows the rate at which the hydrogen peroxide is neutralized, particularly during the initial two hours, by a catalyst element that includes a P-metal. This reduction in rate of peroxide neutralization provides a more effective solution for killing certain microorganisms and fungi.

Claims (12)

1. A contact lens disinfecting system comprising:

a contact lens, peroxide disinfecting solution comprising 0.5 wt. % to 6 wt. % hydrogen peroxide or a chemical precursor of hydrogen peroxide; and a P-metal modulating compound, wherein the P-metal modulating compound is taurine, and the molar concentration of the P-metal modulating compound is less than the molar concentration of the hydrogen peroxide in the disinfecting solution; and

a contact lens disinfecting apparatus comprising a container adapted to contain a quantity of the peroxide disinfecting solution, and a cap member that engages the container, the cap member including a lens supporting assembly that includes a lens support structure and a catalytic element that includes a P-metal, wherein the P-metal modulating compound is present at an effective concentration of 0.08 wt. %-2.0 wt. % such that the catalytic element catalyzes the decomposition of the hydrogen peroxide in the disinfecting solution with a pseudo first-order, half-life of hydrogen peroxide over an initial sixty minutes of neutralization that is 1.25 times to 3 times greater with the P-metal modulating compound in the solution than in the absence of the P-metal modulating compound, and wherein the pseudo first-order, half-life of hydrogen peroxide over an initial sixty minutes of neutralization is from 12 minutes to 30 minutes.

2. The disinfecting system of claim 1 wherein the pseudo first- order, half-life of hydrogen peroxide over the initial sixty minutes is from 14 minutes to 22 minutes, and the concentration of hydrogen peroxide after an initial six hours of neutralization is less than 150 ppm.

3. The disinfecting system of claim 1 wherein the disinfecting solution further comprises a low foam surfactant, particularly a polyoxyethylene/polyoxypropylene condensation polymer selected from the group consisting of Pluronic® L42, Pluronic® L43, Pluronic® L61, Pluronic® L81, Pluronic® 31R1, Pluronic® 31R2, Pluronic® 25R1, Pluronic® 17R1, Pluronic® 17R2, Pluronic® 12R3 and Pluronic® 17R4.

4. The disinfecting system of claim 1 wherein the P-modulating compound provides a hydrogen peroxide neutralization profile that is more effective against Candida albicans by 0.8 log-kill or greater after an initial four hours of neutralization than an equivalent contact lens disinfecting solution but without the P-metal modulating compound.

5. The disinfecting system of claim 1 wherein the P-metal-modulating compound is present at a concentration of from 0.08 wt. % to 1.0 wt. %.

6. The disinfecting system of claim 1 wherein the molar ratio of the hydrogen peroxide to the P-metal modulating compound is from 3:1 to 100:1.

7. A contact lens disinfecting system comprising:

a contact lens, peroxide disinfecting solution comprising 0.5 wt. % to 6 wt. % hydrogen peroxide or a chemical precursor of hydrogen peroxide and a P-metal modulating compound, wherein the P-metal modulating compound is taurine, and

a contact lens disinfecting apparatus comprising a container adapted to contain a quantity of the peroxide disinfecting solution, and a cap member that engages the container, the cap member including a lens supporting assembly that includes a lens support structure and a catalytic element that includes a P-metal, wherein the P-metal modulating compound is present at an effective concentration of 0.08 wt. %-2.0 wt. % such that the catalytic element catalyzes the decomposition of the hydrogen peroxide in the disinfecting solution with a pseudo first-order, half-life of hydrogen peroxide over an initial sixty minutes of neutralization that is 1.25 times to 3 times greater with the P-metal modulating compound in the solution than in the absence of the P-metal modulating compound.

8. The disinfecting system of claim 7 wherein the pseudo first-order, half-life of hydrogen peroxide over the initial sixty minutes of neutralization is from 1.25 times to 2 times greater with the P-metal modulating compound in the solution than in the absence of the P-metal modulating compound.

Assignments (3)
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →